Insights

Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operations under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.
April 22, 2020

Security and Supply of Blood Derived Ancillary Materials May Need to Be Rethought in the Era of Novel Viral Outbreaks: A Webinar Hosted by HCATS & Sexton Biotechnologies

Read More
December 9, 2019

Harmonizing Core Platforms in the Delivery of Patient-Specific Cell Therapies to Accelerate Patient Access to Life-Changing Treatments

As our knowledge of human biology has grown, the newly found information has been leveraged to devise increasingly complicated treatments. This began with small molecule ...

Read More
September 17, 2019

Dr. Preti Answers Questions in ISCT’s Talking with Giants

When Robert Preti, PhD, co-founded PCT back in 1999, he already had extensive experience in stem cell processing and other roles from his time with the New York Blood ...

Read More
September 16, 2019

Webinar: The Manufacturing Challenges Facing Cell & Gene Therapy

On Thursday, September 19, 2019, Dr. Robert Preti will join a panel of other cell and gene therapy industry luminaries to highlight the challenges that the industry is ...

Read More
August 22, 2019

Moving Towards Automated Manufacturing for Cell Therapies

As more cell therapy products reach the “finish line” of U.S. Food and Drug Administration (FDA) approval and new regenerative medicine products begin the clinical ...

Read More
July 16, 2019

Improving Starting Material Stability for Cell Therapy Manufacturing

The quality and consistency of starting material can have an enormous impact on downstream manufacturing processes in cell therapy. Recently, Hitachi Chemical partnered ...

Read More
July 10, 2019

Developing & Managing Therapeutic Cell Collection Networks

The quality of starting materials can have an enormous impact on the potency, purity, and safety of a cell therapy product. Flaws in the collection or transportation ...

Read More
April 12, 2019

Phacilitate 2019 Event Recap

Phacilitate is the world’s largest advanced therapies partnering event, bringing together experts and solution providers from all over the world to create the perfect ...

Read More
February 21, 2019

Bloomberg Law Article: Breakthrough Cancer Therapy Stalls in Manufacturing Bottleneck

In a recent Bloomberg Law article, Robert Preti, PhD, discusses how manufacturing bottlenecks are holding up cancer treatments from going to market. There has been a lot ...

Read More
All Posts